BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25810117)

  • 1. Cytomegalovirus reactivation in patients with multiple myeloma.
    Hasegawa T; Aisa Y; Shimazaki K; Ito C; Nakazato T
    Eur J Haematol; 2016 Jan; 96(1):78-82. PubMed ID: 25810117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
    Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A
    Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
    Kim JH; Goulston C; Sanders S; Lampas M; Zangari M; Tricot G; Hanson KE
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1753-8. PubMed ID: 22728249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
    Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
    Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer.
    Han XY
    J Clin Microbiol; 2007 Apr; 45(4):1126-32. PubMed ID: 17287334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
    Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus reactivation following hematopoietic stem cell transplantation.
    Sharma SK; Kumar S; Agrawal N; Singh L; Mukherjee A; Seth T; Mishra P; Mathur S; Dar L; Mahapatra M
    J Infect Dev Ctries; 2013 Dec; 7(12):1003-7. PubMed ID: 24334950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
    Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
    Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients.
    Annibali O; Piccioni L; Tomarchio V; Circhetta E; Sarlo C; Franceschini L; Cantonetti M; Rizzo E; Angeletti S; Tirindelli MC; Scagnolari C; Statzu M; Avvisati G; Riva E
    PLoS One; 2018; 13(7):e0200221. PubMed ID: 30036376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.
    Hussein AA; Al-Antary ET; Najjar R; Al-Hamdan DS; Al-Zaben A; Frangoul H
    Pediatr Blood Cancer; 2015 Jun; 62(6):1099-101. PubMed ID: 25346146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients.
    Cortez KJ; Fischer SH; Fahle GA; Calhoun LB; Childs RW; Barrett AJ; Bennett JE
    J Infect Dis; 2003 Oct; 188(7):967-72. PubMed ID: 14513415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
    Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients.
    Matsuoka K; Iwao Y; Mori T; Sakuraba A; Yajima T; Hisamatsu T; Okamoto S; Morohoshi Y; Izumiya M; Ichikawa H; Sato T; Inoue N; Ogata H; Hibi T
    Am J Gastroenterol; 2007 Feb; 102(2):331-7. PubMed ID: 17156136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.